Open-Label, Non Randomized Phase 2 Study With Safety Run-In Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2017
At a glance
- Drugs PQR 309 (Primary)
- Indications Lymphoid leukaemia; Lymphoma
- Focus Therapeutic Use
- Sponsors PIQUR Therapeutics
- 19 Apr 2017 Study is now investigating the antitumor activity of intermittent dosing schedule of PQR309 along with continuous dosing.
- 19 Apr 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2019.
- 19 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Oct 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History